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Drug uSe in 
general MeDical 
SettingS
Resource Guide 
This guide is designed to assist clinicians serving adult patients in screening for drug use.  The NIDA 
Quick Screen was adapted from the single-question screen for drug use in primary care by Smith et 
al. 2010 (available at http://archinte.ama-assn.org/cgi/reprint/170/13/1155) and the National 
Institute on Alcohol Abuse and Alcoholism's Helping Patients Who Drink Too Much: A Clinician's 
Guide Updated 2005 Edition (available at http://pubs.niaaa.nih.gov/publications/Practitioner/
CliniciansGuide2005/clinicians_guide.htm).  The NIDA-modified ASSIST was adapted from the 
World Health Organization (WHO) Alcohol, Smoking and Substance Involvement Screening Test 
(ASSIST), Version 3.0, developed and published by WHO (available at http://www.who.int/
substance_abuse/activities/assist_v3_english.pdf). 
This pamphlet is in the public domain and may be reproduced.
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Introduction 
 
This Resource Guide is intended to provide 
clinicians serving adult populations∗ in 
general medical settings with the screening 
tools and procedures necessary to conduct 
screening, brief intervention, and/or 
treatment referral for patients who may 
have or be at risk of developing a substance 
use disorder.  Screening and brief 
intervention provides an opportunity for 
clinicians to intervene early and potentially 
enhance medical care by increasing 
awareness of the likely impact of substance 
use on a patient’s overall health. 
 
Why screen for drug use (including 
tobacco, alcohol, illicit [i.e., illegal], 
and nonmedical use of prescription 
drugs)?  
 Drug use (licit or illicit) is harmful and 
has many adverse consequences. 
Multiple physical health, emotional, and 
interpersonal problems are associated 
with illicit drug use. Cardiovascular 
disease, stroke, cancer, HIV/AIDS, 
anxiety, depression, sleep problems, as 
well as financial difficulties and legal, 
work, and family problems can all result 
from or be exacerbated by drug abuse.1 
 
 The use of illicit drugs is more common 
than you might think. In 2010, an 
estimated 22.6 million Americans aged 
12 or older (~8.9 percent of the 
population) were current illicit drug 
users, which means they had used an 
illicit drug during the month prior to the 
survey. About 1 in 5 Americans aged 
18−25 used illicit drugs in the past 
month.2 
 
 Only a fraction of individuals who need 
specialty treatment for drug or alcohol 
addiction actually receive it each year. 
                                                 
∗ This resource guide does not specifically address the 
unique considerations that must be taken into account 
when screening adolescents or pregnant women. 
In 2010, of the 23.1 million persons aged 
12 or older who needed specialized 
treatment for a drug or alcohol problem, 
most—almost 21 million—did not 
receive it.3 Routine screening for 
substance use disorders could alter this 
statistic and get more people the help 
they need.  
 
 Using screening and brief intervention 
procedures in general medical settings 
can make a difference in drug use 
behaviors. Research has demonstrated 
that screening and brief intervention can 
promote significant reductions in alcohol 
and tobacco use.4,5,6 A growing body of 
literature also suggests benefits of 
screening and brief intervention for illicit 
or nonmedical prescription drug use as 
well.7,8 
 
 
How do you screen and provide 
feedback? 
As a medical provider, you are an important 
figure in your patients’ lives. In a very short 
conversation, you have a wonderful 
opportunity to let your patients know if and 
how their drug use may be putting their 
health at risk. 
 
The Five A’s of Intervention (Ask, Advise, 
Assess, Assist, Arrange) can be a useful 
framework for encouraging patients to quit 
smoking and may also be useful for 
screening and providing feedback related to 
other drug use. 
 
ASK – Screening is the first A because it asks 
one or more questions related to drug use.  
 
ADVISE – The second A involves strong 
direct personal advice by the provider to the 
patient to make a change, if it is clinically 
indicated. 
 
ASSESS – The third A refers to determining 
how willing a patient is to change his or her 
behavior after hearing the provider’s advice. 
 
 3 
 
ASSIST – The fourth A refers to helping the 
patient make a change if he/she appears 
ready. 
 
ARRANGE – The final A is to refer the 
patient for further assessment and 
treatment, if appropriate, and to set up 
followup appointments. 
 
If you are not already doing so, we encourage you to incorporate drug use screening and 
brief intervention into your practice. The remainder of this Resource Guide provides detailed 
information to begin screening for: 
 
  
 
Alcohol 
 
 
 
 
 
Tobacco 
 
 
 
 
 
 
Nonmedical  
Prescription Drug Use 
 
 
 
 
 
Illicit Drugs 
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Before you begin screening patients  
 
While most health care settings have 
established processes and procedures for 
patient screening of health conditions such 
as high blood pressure, cholesterol, breast 
or prostate cancer, etc., drug abuse 
screening in general medical settings 
involves additional practical 
considerations:9,10 
 Determine staffing roles, including who 
will administer the screening instrument; 
discuss results with patients; and 
intervene and/or refer when necessary. 
 
 Train designated staff to conduct 
screening, intervention, and referral. 
 
 Decide how screening results will be 
used and develop a procedure for 
handling positive and negative results. 
Note: Screening is not a full assessment; 
refer patients for a full assessment if a 
problem is indicated by the screen or 
through discussion with the patient. 
 
 Apply existing office procedures to 
screening practices, including patient 
documentation, consent procedures, 
confidentiality and HIPAA procedures, 
storage of records, and patient flow. 
 
 Obtain reimbursement information for 
your State.  
o In 2007, the Centers for Medicare 
and Medicaid Services (CMS) 
adopted new codes for alcohol and 
substance abuse assessment and 
intervention services in the 
Healthcare Common Procedure 
Coding System (HCPCS).  
o In January 2008, the American 
Medical Association (AMA) adopted 
Current Procedural Terminology 
(CPT) codes for screening and brief 
intervention, and new Medicare “G” 
codes became available that parallel 
the CPT codes (see 
http://www.samhsa.gov/prevention/
SBIRT/coding.aspx for more 
information).   
 
 Establish relationships and linkages with 
external providers who will accept 
referrals for additional assessment 
and/or drug treatment.  
 
 Consider patient reading level when 
providing educational and support 
materials. Because it is often difficult to 
determine reading level, particularly in 
emergency room situations, consider 
using materials developed for an 8th 
grade reading level.  An important 
resource is NIDA’s easy-to-read website 
for adults with low literacy.  This 
website, which contains information 
about drugs, addiction, recovery and 
treatment, is available at 
http://easyread.drugabuse.gov. 
 
 Deal with severe, immediately life-
threatening medical consequences of 
substance abuse as you would any other 
medical emergency. 
o If same-day substance abuse 
treatment assessment is not 
available, transfer patient to the 
emergency room or admit to the 
hospital.  
o Arrange alternative transportation 
for patients under the influence of 
drugs, alcohol, or medication that 
would impair their driving.  For these 
patients, the brief intervention 
should focus on crisis management. 
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Screening Your Patients: 
Step 1: Ask about past year drug use 
Step 2: Begin the full NIDA-Modified ASSIST  
Step 3: Determine risk level  
 
The NIDA Quick Screen 
 
Step 1: ASK about past year drug use  
 
The NIDA Quick Screen and NIDA-modified ASSIST are appropriate for patients age 18 or 
older.  You may deliver it as an interview and record patient responses, or read the questions 
aloud and have the patient fill out responses on a written questionnaire. It is recommended 
that the person administering the screening review the sample script to introduce the 
screening process. The script offers helpful language for introducing what can be a sensitive 
topic for patients.     
Introduce yourself and establish 
rapport.   
Before you begin the interview, please read 
the following to the patient: 
 
Hi, I’m __________, nice to meet you. If it’s okay 
with you, I’d like to ask you a few questions that will help me give you better medical care. The 
questions relate to your experience with alcohol, cigarettes, and other drugs. Some of the substances 
we’ll talk about are prescribed by a doctor (like pain medications). But I will only record those if you 
have taken them for reasons or in doses other than prescribed. I’ll also ask you about illicit or illegal 
drug use––but only to better diagnose and treat you. 
 If the patient declines screening, advise the patient that you respect that decision but 
would like to inform him/her about the potential harms of drug use. 
 
Ask patients about past year drug use using the NIDA Quick Screen.  
 
 Without being judgmental or confrontational, ask the 
patient how many times, within the past year, has he or 
she used any of the substances listed on the NIDA Quick 
Screen (http://www.drugabuse.gov/nmassist/).  
  If the patient says “Never” for all drugs in Quick Screen, 
reinforce abstinence. For example, you may say “It is 
really good to hear you aren’t using drugs. That is a very 
smart health choice.” Screening is complete.   
 If patient says “Never” to alcohol use, Advise patient to 
stay within these limits:   
For healthy men under the age of 65: No more than 4 
drinks per day AND no more than 14 drinks per 
week. 
For healthy women under the age of 65 and not 
pregnant (and healthy men over the age of 65): No 
more than 3 drinks per day AND no more than 7 
drinks per week. 
Reminder: 
 
Patients should be advised 
of the limits of 
confidentiality and 
insurance coverage for 
conditions occurring under 
the influence of alcohol or 
illicit drugs (these vary by 
State and provider). 
Reminder: 
 
Many people don’t know 
what counts as a standard 
drink (e.g., 12 oz beer, 5 oz 
wine, 1.5 oz liquor).  
 
For information, please see 
http://pubs.niaaa.nih.gov/p
ublications/Practitioner/Cli
niciansGuide2005/clinician
s_guide13_p_mats.htm 
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 If patient answers indicate one or more days of heavy drinking, patient is an at-risk 
drinker.   
Please see NIAAA website “How to Help Patients Who Drink Too Much: A Clinical 
Approach”: 
http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/clinicians
_guide.htm, for information on how to Assess, Advise, Assist, and Arrange help 
for at risk drinkers or patients with alcohol use disorders 
 If patient answers indicate use of tobacco: Any current tobacco use places a patient at 
risk.  Advise all tobacco users to quit.  For more information on smoking cessation, 
please see “Helping Smokers Quit: A Guide for Clinicians” 
http://www.ahrq.gov/clinic/tobacco/clinhlpsmksqt.htm  
 If the patient says “Yes” for use of illegal or prescription drugs for nonmedical 
reasons proceed to Step 2 and begin the NIDA-Modified ASSIST.    
 
Step 2: Begin the NIDA-Modified ASSIST 
(http://www.nida.nih.gov/nidamed/screening/nmassist.pdf). 
Ask the patient about lifetime drug use.   
 If patient reports “No” to lifetime use of all drugs listed in Question 1, remind them 
that their responses to the NIDA Quick Screen indicate they have used an illegal or 
prescription drug for nonmedical reasons within the past year.  Repeat Question 1.   
 If patient indicates that the drug used is not listed, please indicate “Yes” next to 
other and continue to Question 2. 
 If a patient reports “Yes” to lifetime use of substances listed in Question 1, proceed to 
Question 2, which asks questions about use in the last three months. 
 If patient reports “Never” to Question 2 (i.e., no use in the past three months), 
proceed to Question 6. 
 If patient reports use of any drugs in the past three months, complete Questions 3-8. 
Step 3: Determine risk level 
 
Score the NIDA-Modified ASSIST for illicit and nonmedical prescription drug 
use.  
 For each substance, add up the scores received for Questions 2–7. This is the 
Substance Involvement (SI) score.  Do not include the results from either Step 1 (Quick 
Screen), Question 1 or Question 8 in your SI score. The patient will receive an SI score 
for each substance endorsed, not a cumulative score. Therefore, the patient’s risk 
level may differ from drug to drug.  
 
 Use the resultant SI score to identify patient’s risk level. If more than one substance 
is reported, focus intervention on the substance with the highest score. 
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Reminder: 
 
Use clinical 
judgment if the 
patient reports use 
of multiple drugs 
but does not score 
highly on any of 
them (i.e., consider 
an intervention).  
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Step 4: Brief Intervention 
Review results with patient, then:  
• Advise patient about drug use 
• Assess readiness to quit 
• Assist patient in making changes 
• Arrange treatment or follow-up 
care 
Reminders to improve patient rapport:  
• Avoid tone that the patient might think is 
judgmental or confrontational. 
• Show an interest in what the patient’s life is like. 
• Acknowledge the patient’s current view of 
his/her drug use. 
• Signal to the patient that having mixed feelings 
about a drug use problem is normal. 
• Highlight patient confidentiality (and its 
limitations). 
 
Screen, then Intervene:  Conducting a 
Brief Intervention 
 
Step 4: Advise, Assess, Assist and Arrange 
This brief intervention gives patients a chance to learn about their drug use—especially as it 
pertains to their health—from an objective third party with medical training. It relies on the 
premise that advice from an expert has been shown to promote change.11,12  
Begin by reviewing screening results with the patient. 
 Ask permission to have a short discussion 
about the screening results.  
 Report back the types and amounts of use 
reported (giving patients the NIDA-Modified 
ASSIST tally sheet may be helpful).   
o Allow the patient to correct 
omissions so you get the full picture 
of use.   
o Prompt the patient: “Tell me more 
about your use of drug X and Y” (for 
each drug the patient reported).  
 If the patient has used within the past 3 months, review other ASSIST responses. 
 
ADVISE - Provide medical advice about the patient’s drug use. 
 Explain that it is your role as 
his/her medical provider to 
convey health 
recommendations.  
 
 Recommend quitting before 
problems (or more problems) 
develop.  Give specific medical 
reasons. 
o Medically supervised 
detoxification may be 
necessary for discontinuing 
use of some drugs (e.g., benzodiazepines). 
 
 When appropriate, educate patients on the 
following: 
o Use of even small amounts of drugs, including 
alcohol or tobacco, may negatively impact 
health and performance (e.g., driving or 
operating machinery). 
o Because drug intoxication can lead to impaired 
Reminder: 
The screen is only one 
indicator of a patient’s 
potential drug use problem.  It 
is not a substitute for clinical 
judgment, which you should 
use to determine when an 
intervention is warranted.  
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judgment and risky behaviors, refer all sexually active patients for confidential 
testing for HIV and other sexually transmitted diseases or provide an onsite testing 
opportunity, if they do not know their status or have not been tested recently.  
Encourage all patients to practice safe sex. 
o Refer all patients with past or current injection drug use (Question 8) for HIV and 
Hepatitis B/C testing if they have not been tested twice over a 6-month span 
following their last injection.  
 Make referrals to evaluate suspected co-occurring conditions (e.g., psychiatric 
consultation for depressed, inattentive, or anxious patients or pain specialist 
consultation for patients seeking narcotic prescriptions for chronic nonmalignant 
pain). 
 Provide recommendations based on risk level: 
 
Risk level Recommendation 
High risk A strong recommendation to change substance use is essential. Consider making a 
statement such as: “Based on the screening results, you are at high risk of having 
or developing a substance use disorder. It is medically in your best interest to 
stop your use of [insert specific drugs here]. I am concerned that if you do not 
make a change quickly, the consequences to your health and well-being may be 
serious.” Include a referral for additional assessment (the NIDA-Modified ASSIST 
provides a risk level, but not a diagnosis of abuse or dependence). Let the patient 
know that the assessment will determine whether they have a diagnosis of 
substance abuse or dependence and if substance abuse treatment is indicated.   
Whether to attend treatment will be the patient’s decision. 
• Specific examples of harm for different problem drug categories may be 
helpful. 
• Emphasize that there are many ways to change substance use behavior (e.g., 
community treatment programs, self-help groups, medications, etc.).  
• Emphasize that treatment is often on an outpatient basis and programs are 
often accommodating of concerns like maintaining employment, insurance 
reimbursement, child care, etc., depending on the patient’s concerns. 
Moderate risk Consider beginning the discussion by saying, “Based on the screening results, you 
are at moderate risk of having or developing a substance use disorder. It is 
medically in your best interest to change your use of [insert specific drugs here].” 
• Add information that is specific to the drugs the patient uses.  
• Express your concern about specific ways drugs might negatively impact your 
patient’s life (e.g., health, relationships, work, etc.).  
• Emphasize that there are many ways to change substance use behavior (e.g., 
community treatment programs, self-help groups, medications, etc.).   
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Lower risk Consider having a discussion about acceptable levels of use and the potential for 
future problems. You may begin the discussion by saying “Your screening results 
show you are unlikely to have a substance use disorder. However, people with 
any history of substance use can be at some risk of adverse consequences  and 
developing a disorder especially in times of stress or if they have just started to 
use recently. It is impossible to know in advance whether or not a person will 
become addicted. As your physician I encourage you to only use alcohol 
moderately and responsibly and to avoid using other substances.”  
• Intervention duration may be minimal 
• Use your clinical judgment based on the medical status of the patient and drug 
being used. For example, pregnant women,* youth, people with histories of 
substance use disorders, and others for whom any drug use could potentially 
pose a serious risk may benefit from a complete intervention regardless of 
apparent risk level. 
 
ASSESS the patient’s readiness to quit.  
 Have a conversation about whether the patient is ready to quit. For example, you 
might say something like, “Given what we’ve talked about, do you want to change 
your drug use?” 
 If the patient is unwilling to quit, raise awareness about drugs as a health problem.  
Let patients who are not ready know that you will revisit the issue at future visits and 
have resources available when he/she decides to pursue making a change.    
 If the patient is ready to quit, reinforce current efforts and then assist patient in their 
efforts to make changes that will help them reduce and/or quit their drug use.   
ASSIST patient in making a change.  
 
 Jointly complete a progress note form (Appendix 2) with the patient to document the 
screening results and create a followup plan.  
 Help set concrete (and reasonable) goals for making a change (see Appendix 3: Change 
Plan Worksheet, for more information).  
o Ask interested patients to complete a change plan before they go home.  
o Make a copy without their name or the name of your office on it, give it to them to 
take home, and tell them you will check in on their progress at the next visit. 
o For patients who do not complete a change plan, schedule a second appointment 
to continue the discussion and to complete the change plan. You may provide a 
blank copy for them to take home and ask them to return with it, but some 
patients may need to start again with a fresh copy during their second 
appointment. 
o For patients not interested in completing a change plan, encourage them to set a 
few brief change goals (e.g., cutting back, trying a self-help group); record the 
goals to check progress at the next visit.  
 Prescribe medications for office-based treatment of tobacco, alcohol, or opiate 
addiction, as appropriate. 
                                                 
* Providers should be aware that many States mandate reporting of drug use during pregnancy and that failure to 
do so may be a prosecutable offense.   
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Offer continuing support at followup 
visits. 
• Refer patients as appropriate 
• Schedule follow-up 
• Offer continuing support at follow-up 
 
 
ARRANGE specialty assessment, drug treatment, followup visit. 
• Refer patients as appropriate.  
 
 Because the screening does not 
provide a diagnosis of abuse or 
dependence, refer high-risk patients 
for a full assessment.  For moderate-
risk patients and low-risk patients with 
special concerns (e.g., pregnant 
women, past injection drug users), use clinical judgment to determine whether 
additional assessment is necessary. Use SAMHSA’s treatment locator (see Appendix 5, 
http://findtreatment.samhsa.gov/) or NIDA’s National Drug Abuse Treatment Clinical 
Trials Network List of Associated Community Treatment Programs (see Appendix 5, 
http://www.drugabuse.gov/ctn/) to locate assessment resources. 
 If nearby treatment resources are not available, consider providing support group 
contact information and self-change materials, as well as counseling resources––
clergy or mental health referrals. 
 Obtain a written information release to send the screening results to all providers who 
will receive referrals. 
 
• Schedule a followup appointment within 1–2 weeks for moderate - and high-
risk patients and low -risk patients in certain groups. 
• Offer continuing support at followup visits. 
 
 Annual rescreening is indicated for patients who report any drug use at baseline (even 
with scores of 0−3) and for any other patients about whom you remain concerned. For 
moderate- and high-risk patients, rescreen at next appointment. 
 
 At followup, make targeted recommendations to moderate-, high- and select lower-
risk patients accordingly: 
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Risk level Targeted Recommendations 
High risk Determine 
whether the 
patient 
followed 
through with 
the referral. 
Offer 
additional 
brief 
intervention 
for patients 
who did not 
attend the 
referral. 
 
Make 
additional 
referrals for 
patients who 
missed 
referral. 
 
Obtain records 
of assessment 
and/or 
treatment for 
patients who 
attended 
referral and/or 
treatment. 
 
Discuss ways 
to help 
support 
recommenda-
tions of 
referral 
source. 
 
Moderate 
risk 
Determine 
whether the 
patient 
reduced or 
abstained 
from use. 
For patients 
who did not 
make progress 
with change 
efforts, 
acknowledge 
change is hard, 
repeat brief 
intervention, 
and discuss 
additional 
ways to 
support the 
patients’ 
efforts. 
For patients 
who have 
made changes, 
reinforce 
efforts and 
encourage 
additional 
goal-setting. 
Follow up at 
subsequent 
visits. 
 
 
Lower risk If the patient 
indicated that 
he/she wanted 
to make a 
change, ask 
what, if 
anything, the 
patient 
decided to do 
about 
substance use. 
Encourage 
abstinence 
from tobacco 
and illicit 
drugs and 
advise low-risk 
alcohol users 
to remain 
within 
acceptable 
drinking levels. 
 
On evidence of 
escalation of 
use, conduct 
brief 
intervention. 
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Appendix 1—Recommendations to Address 
Patient Resistance (may not be applicable in every case) 
 
Patient Resistance Scenario Physician Response 
Patient answers “no,” seemingly without 
considering it thoughtfully or is reluctant 
to give details. 
• Gently probe with a question like: “Not even when you were 
in school?” 
• Encourage discussion by saying “go on” or “tell me more.” 
Patient is uncomfortable disclosing 
personal substance use on a form. 
• Let the patient know you will follow up in person about the 
screening.   
• Reinforce that all information provided will be kept 
confidential when possible. 
• If patient is still uncomfortable, skip screening but provide 
information about harms associated with drug use. 
Patient appears ashamed or embarrassed 
about recommendations to change 
substance use behaviors. 
• State that this is a health-related medical recommendation 
and is not meant to judge or stigmatize them.   
• Remind the patient of your role—that physicians have a duty 
to share test results with their patients.  
At-risk patient appears ambivalent to the 
idea of changing his/her substance use 
behavior. 
• Acknowledge the patient’s ambivalence and the fact that 
ambivalence is common. 
• State your concern about specific ways that drugs may 
negatively affect your patient’s health or personal life. 
Patient becomes upset, argumentative. • Do not argue with the patient.  Give the patient time to make 
a decision (unless the condition is life-threatening).  
• Discuss his/her concerns and reflect them back (e.g., convey 
that you understand the patient’s claim that drugs make 
them feel better or that their peers use them). 
Patient resists referral for additional 
assessment 
• Explore concerns about the assessment. 
• Emphasize that referral for an assessment may not mean 
entering substance abuse treatment—and that treatment, if 
recommended, likely will include different options. 
Patient cites barriers to attending the 
referral appointment. 
• Problemsolve about barriers and offer support, such as 
reminder calls, assistance arranging transportation, and child 
care. 
Patient resists the idea of going into 
formal substance abuse treatment. 
• Clearly state that you are not insisting on formal treatment. 
• Explain that treatment is often easier than quitting “cold 
turkey” and  that stopping the use of certain drugs (e.g., 
alcohol, benzodiazepines) without medical supervision can 
be dangerous. 
In followup visits, patient shows no 
progress with change efforts. 
• Acknowledge that change is difficult. 
• Repeat the brief intervention and discuss other ways to 
support the patient’s efforts.   
• Make additional referrals for patients who did not attend the 
referral. 
    
  
   
    
 15 
 
Level of risk associated with different  
Substance Involvement Score ranges for  
illicit or nonmedical prescription drug use 
0–3 Low Risk 
4–26 Moderate Risk 
27+ High Risk 
 
Appendix 2—Sample Progress Note 
 
DATE: 
Time with patient (min): 
Performed by:                                                               Primary Physician: 
 
SCREENING: Circle each substance used and 
record Substance Involvement Score 
 
Substance List:                                   
a. cannabis________________ f. Inhalants________   
b. cocaine_________________g. Sedatives________ 
c. prescription   h. prescription 
amphetamines_____________     opioids_________ 
d. street opioids____________ i. hallucinogens_____  
e. methamphetamine_________________________  
j. Other_____________________________________ 
 
Past 3 months (list 
substances):______________________ 
________________________________ 
 
Biological Test Results:_______________ 
 
IF ALCOHOL USE (circle below):                                                        
 
 
PLAN: 
 
Discussed screening results with patient (check if completed)______ 
 
Provided a Brief Intervention  (check if completed)______ 
 
How ready is patient to change behavior?  Unwilling_____  Tentative______ Ready_______ 
 
Change Plan completed?  Yes ____ (attach)   No ____  N/A ____ 
Change Plan appointment?     Yes ____           No___     N/A ____ 
 
REFERRAL STATUS:    
 
Refer for further assessment?__________ Refused?____________  N/A _______ 
Refer to detox? _____________________ Refused?____________   N/A _______ 
 
FOLLOWUP PLANS:  
 
Date of next appointment to check progress_____________ 
Or, for low-risk patients, rescreen on next RTC___________, or one year (if negative).  
        
 
Provider Signature:________________________Patient Signature:_____________________      
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Appendix 3—Change Plan Worksheet 
 
See http://www.hhs.gov/opa/familylife/tech_assistance/resources/ami-materials.pdf for 
more information and examples. 
 
 
The changes I want to make (or continue making) are:  
The reasons why I want to make these changes are:  
The steps I plan to take in changing are:  
The ways other people can help me are:  
I will know that my plan is working if:  
Some things that could interfere with my plan are:  
What I will do if the plan isn’t working:  
As my doctor, you can help me keep these changes by: 
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Appendix 4—Biological Specimen Testing 
 
Introduction to Biological Testing 
 
Urine drug testing is the most common toxicological test of body fluid samples in general 
medical settings, but you do not need to have a biological testing program to implement a 
drug screening program. The purpose of a biological testing program is to: 
 
 Confirm the presence of a drug or the use of multiple drugs. 
 
 Augment screening and followup conversations (i.e., biological testing should not 
preclude screening). 
 
Users of biological tests should be aware that: 
 
 Biological tests have different windows of detection. For example: 
 
o A positive urine or saliva screen for cocaine and/or heroin likely indicates very 
recent use (past few days/past week), whereas one for marijuana could detect 
marijuana use one month or more in the past.  
 
o It is almost impossible to determine the time of use from hair samples. 
 
 Not all biological screens test for all commonly abused drugs (e.g., MDMA, 
methadone, fentanyl, and other synthetic opioids are not included in many drug 
screens, and these tests must be ordered separately). 
 
 Biological tests examine a sample with a drug concentration at a specific cutoff level 
(see 
http://workplace.samhsa.gov/DrugTesting/pdf/2010GuidelinesAnalytesCutoffs.pdf).  
Therefore, a negative result does not mean drugs have not been used, and a positive 
result may at times reflect consumption of other substances (such as hemp or poppy 
products).  
 
 If tampering is a concern, specimens should be monitored for temperature or 
adulterants; and programs should implement and follow accurate chain-of-custody 
procedures. 
 
Feedback for biological screening results:  
 
 Present results in a matter-of-fact way in conjunction with NIDA-Modified ASSIST 
feedback. 
 
 Re-administer the test if the patient believes the result showed a false positive. 
 
 If the second biological test results are positive, categorize the patient as high risk and 
offer a brief intervention and referral for additional assessment and possible 
treatment.  
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Appendix 5—Additional Resources 
 
Screening Information: 
Henry-Edwards, S.; Humeniuk, R.; Ali, R.; Poznyak, V.; and Monteiro, M. The Alcohol, Smoking and 
Substance Involvement Screening Test (ASSIST): Guidelines for Use in Primary Care. Geneva, 
Switzerland: World Health Organization (WHO), 2008. Available at 
http://www.who.int/substance_abuse/activities/en/Draft_The_ASSIST_Guidelines.pdf.  
 
Center for Substance Abuse Treatment. Alcohol Screening and Brief Intervention (SBI) for Trauma 
Patients: Committee on Trauma Quick Guide. Substance Abuse and Mental Health Services 
Administration, DHHS Publication No. (SMA) 07-4266. Washington, DC: U.S. Government Printing 
Office, 2007. Available at http://www.samhsa.gov/csatdisasterrecovery/featuredReports/01-
alcohol%20SBI%20for%20Trauma%20Patients.pdf.  
 
Center for Substance Abuse Treatment. A Guide to Substance Abuse Services for Primary Care 
Clinicians. Treatment Improvement Protocol (TIP) Series, Number 24. Substance Abuse and Mental 
Health Services Administration, DHHS Publication No. (SMA) 97–3139. Washington, DC: U.S. 
Government Printing Office, 1997. Available at 
http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat5.chapter.45293 . 
 
Brief Intervention Instruction and Additional Information: 
World Health Organization. Brief Intervention for Substance Use: A Manual for Use in Primary Care—
http://www.who.int/substance_abuse/activities/en/Draft_Brief_Intervention_for_Substance_Use.pdf.  
 
National Institute on Alcohol Abuse and Alcoholism’s Helping Patients Who 
Drink Too Much: A Clinician’s Guide: 
http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/clinicians_guide.htm. 
 
SAMHSA’s Treatment Facility Locator:  
  Searchable directory of drug and alcohol treatment programs around the country that treat drug 
abuse, alcoholism, and alcohol abuse problems. 
  Simply enter an address into the “quick search” feature, and you will see a list of substance abuse 
treatment facilities closest to the address. Additional instructions available at 
http://findtreatment.samhsa.gov/images/loc_short.pdf.  
 
NIDA’s National Drug Abuse Treatment Clinical Trials Network List of Associated 
Community Treatment Programs: 
http://www.drugabuse.gov/CTN/ctps.html. 
 
Resources on Certification in Office-Based Buprenorphine: 
http://buprenorphine.samhsa.gov/howto.html. 
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